NASDAQ · Analyst Forecast

Scribe Therapeutics Inc. (SCTX) Stock Forecast & Price Target

$15.77 NASDAQ: SCTX Market Cap $255.19M

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 18, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Scribe Therapeutics Inc. (SCTX), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Scribe Therapeutics Inc., analysts forecast revenue falling from $10.35M in 2026 to $7.00M in 2028; the average estimate for 2028 earnings per share is −$4.64; with published estimates ranging from −$6.27 to −$3.02; 3 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$15.77
Consensus targetThe average of the price targets analysts have published.$51.75
Median targetThe middle target, less affected by a single outlier.$55.00
Highest targetThe most optimistic published target.$60.00
Lowest targetThe most pessimistic published target.$37.00
Difference from priceHow far the consensus target sits from today’s price.+228.2%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2026$7.83M$10.35M$14.42M3
2027$5.07M$6.70M$9.33M3
2028$5.29M$7.00M$9.75M3

Earnings per share forecast

YearLowAverageHighAnalysts
2026−$5.56−$3.68−$2.523
2027−$3.81−$2.52−$1.723
2028−$6.27−$4.64−$3.023

Scribe Therapeutics Inc. (SCTX) forecast — frequently asked questions

What is the analyst price target for Scribe Therapeutics Inc.?

Analysts covering Scribe Therapeutics Inc. (SCTX) have a consensus price target of $51.75, 228.2% above the current price of $15.77. Published targets range from $37.00 to $60.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Scribe Therapeutics Inc.'s earnings?

The average analyst estimate for Scribe Therapeutics Inc. (SCTX) earnings per share in 2028 is -4.64, with individual estimates between -6.27 and -3.02.

How much revenue is Scribe Therapeutics Inc. expected to make?

Analysts forecast Scribe Therapeutics Inc. (SCTX) revenue of $7.00M in 2028, based on 3 published estimates.

How many analysts cover SCTX?

3 analysts contribute estimates for Scribe Therapeutics Inc. (SCTX). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.